Phreesia, Inc. (NYSE:PHR) reported mixed fourth-quarter financial results and cut its FY27 sales guidance on Monday.
Phreesia reported fourth-quarter earnings of 2 cents, missing the consensus of 7 cents. Sales reached $127.07 million, up 16% year-over-year, beating the consensus of $126.62 million.
The average number of healthcare service clients (AHSCs) was 4,658 in the quarter, up 7% year-over-year.
Phreesia on Monday lowered its fiscal 2027 revenue outlook to $510–$520 million, down from $545–$559 million, citing reduced visibility into pharma client spending and weaker-than-expected commitments for the second half of the year.
“We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 …
This post was originally published here
